Cambridge Heart, Inc. (NASDAQOTCBB:CAMH)

CAPS Rating: No stars

The Company is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease.

Recs

1
Player Avatar paulmacdo (< 20) Submitted: 4/28/2007 11:58:18 AM : Outperform Start Price: $3.36 CAMH Score: -141.03

This technology will become the standard for determining whether defibs are needed or not. Major clinical trials all support this. Another larege clinical trial is due in Nov, 2007. Insurance coverage already in place and more to come. Recent marketing colaboration with STJ is going to propel sales and adoption. NASDAQ listing will also add to PPS appreciation. CAMH will explode over the 2 years.

Featured Broker Partners


Advertisement